Product Description.:
Liquid , clear , clear
Virasal is a topical preparation containing
27.5% salicylic acid in a proprietary film-forming
vehicle that comprises isopropyl alcohol,
butyl acetate, polyvinyl butyral, isopropylmetacresol,
trimethyl pentanyl diisobutyrate,
phenic acid, and acrylates copolymer. The
pharmacologic activity of Virasal is generally
attributed to the keratolytic activity of salicylic
acid, which is incorporated into a polyacrylic,
film-forming virucidal vehicle designed to cover
the wart without the need for a bandage. The
structural formula of salicylic acid is:
Clinical pharmacology
Although the exact mode of action for salicylic
acid in the treatment of warts is unknown,
its activity appears to be associated with its
keratolytic action, which results in mechanical
removal of epidermal cells infected with wart
viruses.
The virucidal complex incorporated into
Virasal?s proprietary vehicle is designed to
help reduce risk of reinfection at the wart site,
as well as prevent viral contamination of the
product under normal usage.
Indications and uses
Virasal is indicated for the topical treatment and
removal of common warts and plantar warts.
Contraindications
Patients with diabetes or impaired blood
circulation should not use Virasal. Virasal also
should not be used on moles, birthmarks, and
unusual warts with hair growing from them, or
warts on the face.
Precautions
Virasal is for external use only. Do not permit
Virasal to contact eyes or mucous membranes.
If contact with eyes or mucous membranes
occurs, immediately flush with water for 15
minutes. Virasal should not be allowed to
contact normal skin surrounding wart, since
localized irritation may occur. Treatment should
be discontinued if excessive irritation occurs.
Virasal is flammable. Keep away from fire or
flame. Keep bottle tightly capped when not in
use.
Adverse reactions
A localized irritant reaction may occur if Virasal
is applied to the normal skin surrounding the
wart. Any irritation may normally be controlled
by temporarily discontinuing use and by
applying the medication only to the wart site
when treatment is resumed.
Dosage and administration
Prior to applying Virasal, soak wart in warm
water for five minutes. Remove any loosened
tissue by gently rubbing with a brush,
washcloth, or emery board. Dry the wart
site thoroughly. Using the brush applicator
supplied, apply Virasal twice to the entire
wart surface, allowing the first application to
dry before applying the second. Continue
treatment once or twice a day as directed by a
physician. Be careful not to apply to
surrounding skin.
Clinically visible improvement normally occurs
during the first or second week of therapy.
Maximum resolution may be expected after
four to six weeks of Virasal use.
How supplied
Virasal is supplied in 10 ml amber bottles with
a brush applicator (NDC 42783-312-10).
Store at controlled room temperature,
15? to 30? C (59? to 86? F).
Manufactured for:
Elorac, Inc.
Vernon Hills, IL 60061
U.S. Patent Pending
?2011 Elorac, Inc. 1/2011 221619
(27.5% Salicylic Acid
Antiviral Film-Forming Vehicle)
